ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events

May 07, 2024 01:25 AM AEST | By Cision

ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events — Image source: Kalkine Media

Recent News

Altech Batteries (ASX:ATC, FRA:A3Y) Overcomes Silumina Anodes™ Hurdles...

Market Jitters Shake ASX200 as Trade Tensions and Rate Cut Expectation...

Wesfarmers Flags Changing Consumer Trends Amid ASX200 Landscape Shifts

SiteMinder Eyes Stronger Revenue Momentum in H2, Targets ASX200 Growth

TOKYO, May 7, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website. The company will have a presence at the American Society for Immunology (AAI) from May 3rd to 7th, the Association for Research in Vision and Ophthalmology (ARVO) from May 5^th to 9^th, and CYTO 2024 presented by the International Society for Advancement of Cytometry (ISAC) from May 4^th to 8^th. The events will showcase both internal research and development achievements as well as presentations from VisionSort customers on the application of the platform to advance research and therapeutic development efforts.

The new ThinkCyte website was developed with the user experience in mind.

"A year ago we launched VisionSort and had just been recognized for technology innovation at CYTO, the premiere international cytometry meeting," said Janette Phi, Chief Business Officer at ThinkCyte. "Since then we've had the privilege of working closely with our innovation-minded early adopter customers who have been instrumental in pushing the real-world applications of what this technology can do. The diversity of presentations this month and the new website reflects this growth and we look forward to another year of helping our customers advance cell-based R&D efforts in new and exciting ways."

Developed with the user experience in mind, the updated site includes many new features including:

Streamlined and user-friendly explanations of Ghost Cytometry^TM, the core technology inside VisionSort
Easier access to VisionSort Resources including Application Notes, Publications, Posters, and Videos
More info on VisionSort values for Cell Therapy R&D, Drug Discovery, & Disease Profiling
A new Partnering Page for life science technology and Biopharma companies seeking to accelerate R&D of novel therapeutics with AI-based approaches.

For more information about ThinkCyte's upcoming events, visit: https://thinkcyte.com/conferences/https://doi.org/10.1016/j.stemcr.2023.12.001

About ThinkCyte

ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company's flagship product, VisionSort, is the world's first AI-based, dual-mode fluorescence and morphometric cell sorting platform and it partners with major global biopharmaceutical companies and leading academic research institutes to further drive groundbreaking research. For more information, please visit www.thinkcyte.com.

To learn more about VisionSort, the commercially available platform powered by Ghost Cytometry, visit https://thinkcyte.com/product/ or email [email protected]. To learn more about research partnerships or other partnering opportunities with ThinkCyte, visit https://info.thinkcyte.com/partnership or email [email protected].

Photo - https://mma.prnasia.com/media2/2405458/TC_New_Web_Site_on_PC.jpg?p=medium600

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.